A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).

Background: Despite the improvements in diagnosis and treatment, colorectal cancer (CRC) is the second cause of cancer deaths in both sexes. Therefore, research in this field remains of great interest. The approval of bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal...

Descripción completa

Detalles Bibliográficos

Publicado en:	BMC Cancer Vol. 15; no. 1; pp. 69 - 70
Autores principales:	Avallone, Antonio, Piccirillo, Maria Carmela, Aloj, Luigi, Nasti, Guglielmo, Delrio, Paolo, Izzo, Francesco, Di Gennaro, Elena, Tatangelo, Fabiana, Granata, Vincenza, Cavalcanti, Ernesta, Maiolino, Piera, Bianco, Francesco, Aprea, Pasquale, De Bellis, Mario, Pecori, Biagio, Rosati, Gerardo, Carlomagno, Chiara, Bertolini, Alessandro, Gallo, Ciro, Romano, Carmela
Formato:	research randomized controlled trial Journal Article
Publicado:	BioMed Central 2015
Acceso en línea:	Ver este registro en EBSCOhost